哈三联(002900) - 2025 Q2 - 季度业绩预告

Harbin Sanlian Pharmaceutical Co., Ltd. 2025 H1 Earnings Forecast H1 2025 Performance Forecast The company anticipates a significant year-over-year decline and a net loss for the first half of 2025 H1 2025 Performance Forecast | Item | Current Period (H1 2025) | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss: RMB 98.00 million - 80.00 million | Profit: RMB 26.27 million | | YoY Change | Decline: 473.03% - 404.52% | - | | Net Profit Excl. Non-recurring Items | Loss: RMB 95.00 million - 77.00 million | Profit: RMB 21.13 million | | YoY Change | Decline: 549.50% - 464.33% | - | | Basic Earnings Per Share (EPS) | Loss: RMB 0.30/share - 0.24/share | Profit: RMB 0.08/share | Communication with the Accounting Firm The company clarifies that the financial data in this earnings forecast has not been audited by an accounting firm - The financial data in this earnings forecast has not been audited by an accounting firm[4] Explanation of Performance Fluctuation The shift from profit to loss is driven by lower product prices, increased depreciation, and inventory provisions Decline in Sales Prices Product selling prices fell due to national procurement policies and market competition, reducing revenue and gross profit - Product sales prices declined due to national drug procurement policies and intensified market competition[6] H1 2025 Forecasted Impact of Price Decline | Metric | H1 2025 Forecast | YoY Change | | :--- | :--- | :--- | | Revenue | RMB 413 million | Decrease of RMB 110 million | | Gross Profit | - | Decrease of RMB 107 million | Operating Costs and Period Expenses Depreciation and financial expenses increased, while selling and R&D expenses decreased - Operating costs remained relatively stable, but depreciation expenses increased significantly by over RMB 14 million YoY due to the capitalization of construction projects[7] - Overall period expenses decreased, with a combined reduction of over RMB 27 million in selling and R&D expenses, though financial expenses rose by over RMB 12 million[7] Provision for Inventory Impairment An inventory impairment provision of approximately RMB 11 million is expected for H1 2025 due to lower product selling prices - An inventory impairment provision of approximately RMB 11 million is expected for H1 2025 due to declining sales prices[7] Other Relevant Information The company states this forecast is a preliminary estimate and advises investors to refer to the final H1 2025 report - This earnings forecast is a preliminary estimate by the finance department; final data will be in the official H1 report[8]